Drugs / INI-4001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06302426 | Jul 2024 → Oct 2026 expected | neoplasm | Inimmune Corporation | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-29 | Inimmune Corporation | Inimmune to Present Trial-in-Progress Poster on First-in-Human Study of INI-4001, a Novel TLR7/8 Agonist, at ASCO 2025 inimmune.com ↗ |
| 2024-07-24 | Inimmune Corporation | Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist inimmune.com ↗ |
| 2023-12-01 | Inimmune Corporation | Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023 inimmune.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INI-4001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06302426 ↗ |
| Action | Activate | “TLR7/8 agonist” NCT06302426 ↗ |
| Modality | Small molecule | “INI-4001 is a small molecule TLR7/8 agonist” NCT06302426 ↗ |
| Route | Intravenous | “INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle.” NCT06302426 ↗ |
| Target | TLR7 | “TLR7/8 agonist” NCT06302426 ↗ |